ENOXAPARIN SODIUM Drug Interactions
Also known as: Enoxaparin Sodium
Enoxaparin Sodium is a type of medicine known as a blood thinner, specifically a low molecular weight heparin. It works by helping to prevent and treat dangerous blood clots, such as those that can form in the legs (deep vein thrombosis or DVT) or travel to the lungs (pulmonary embolism). This medication is also used to help manage certain heart conditions like unstable angina or heart attacks.ENOXAPARIN SODIUM has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with enoxaparin significantly increases your risk of bleeding, which can be serious or even life-threatening. This includes bleeding from the stomach, intestines, or other body parts.
Mechanism
Naproxen, an NSAID, inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Enoxaparin is a low molecular weight heparin that directly inhibits Factor Xa, preventing clot formation. The concurrent use results in an additive antiplatelet and anticoagulant effect, profoundly increasing the risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding events. Studies show that combining NSAIDs with anticoagulants can increase the risk of serious GI bleeding by 3 to 15 times compared to anticoagulants alone. Symptoms may include black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from cuts. This combination should generally be avoided due to the high bleeding risk. If concurrent use is absolutely necessary, it should be done with extreme caution under close medical supervision, with frequent monitoring for signs and symptoms of bleeding. Consider alternative pain management strategies that do not involve NSAIDs, or use the lowest effective dose of naproxen for the shortest possible duration. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk.
Combining etodolac with enoxaparin significantly increases your risk of bleeding, which can be severe and life-threatening. It is generally recommended to avoid this combination.
Mechanism
Etodolac, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa. Enoxaparin is a low molecular weight heparin that directly inhibits Factor Xa, preventing clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a heightened risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other serious bleeding events. The risk of major bleeding can be several-fold higher (e.g., 3-15 times higher for GI bleeding) compared to either drug alone, with potentially fatal outcomes. This combination should generally be avoided. If concurrent use is unavoidable, patients require very close monitoring for signs of bleeding (e.g., melena, hematemesis, bruising, epistaxis) and blood counts. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. If an NSAID is absolutely necessary, a COX-2 selective NSAID might be considered with extreme caution, but the risk remains significant.
Combining aspirin with enoxaparin significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided unless specifically directed and closely monitored by your doctor.
Mechanism
Aspirin inhibits platelet aggregation irreversibly through cyclooxygenase-1 (COX-1) inhibition, reducing the blood's ability to clot. Enoxaparin, a low molecular weight heparin, directly inhibits Factor Xa, further impairing the coagulation cascade. The additive antiplatelet and anticoagulant effects lead to a synergistic increase in bleeding risk.
Clinical Management
Patients are at a substantially increased risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding events. The risk of major bleeding can be several-fold higher compared to using either drug alone, potentially leading to hospitalization or life-threatening consequences. This combination should generally be avoided due to the high bleeding risk. If concurrent use is absolutely necessary, such as for specific cardiovascular indications, patients require extremely close monitoring for signs of bleeding (e.g., black/tarry stools, unusual bruising, nosebleeds). Gastroprotective agents (e.g., PPIs) may be considered, and the lowest effective doses of both drugs should be used for the shortest possible duration. Regular assessment of complete blood count is recommended.
Combining ibuprofen with enoxaparin significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided due to the heightened risk of serious complications.
Mechanism
Ibuprofen, an NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Enoxaparin, a low molecular weight heparin, directly inhibits Factor Xa, preventing clot formation. The concurrent use of these agents leads to additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other serious bleeding events. Studies suggest the risk of major bleeding can be several-fold higher compared to either drug alone. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies or a COX-2 selective NSAID with extreme caution, and only under strict medical supervision. Monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising, nosebleeds) and hemoglobin levels. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk if NSAID use is unavoidable.
Combining indomethacin with enoxaparin significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor will likely avoid this combination or monitor you very closely.
Mechanism
Indomethacin, an NSAID, inhibits prostaglandin synthesis, which reduces platelet aggregation and can damage the gastrointestinal mucosa, increasing bleeding risk. Enoxaparin is a low molecular weight heparin that directly inhibits Factor Xa, preventing clot formation. The additive antiplatelet effect of indomethacin and the anticoagulant effect of enoxaparin lead to a synergistic increase in bleeding risk.
Clinical Management
This combination significantly elevates the risk of major bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other site-specific bleeding. The risk of serious GI bleeding can be 3 to 15 times higher compared to anticoagulant monotherapy. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, patients require very close monitoring for signs of bleeding (e.g., black stools, easy bruising, nosebleeds). Consider alternative pain management strategies that do not increase bleeding risk, or use a gastroprotective agent if an NSAID is absolutely necessary.
Combining celecoxib (an NSAID) with enoxaparin (a blood thinner) significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Celecoxib, like other NSAIDs, inhibits prostaglandin synthesis, which can impair platelet function and disrupt the integrity of the gastrointestinal mucosa. Enoxaparin directly inhibits clotting factors, primarily Factor Xa, leading to reduced blood clot formation. The concurrent use of these agents results in an additive antihemostatic effect.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (ulcers, hemorrhage), intracranial hemorrhage, and other serious bleeding events. The risk of major bleeding can be several-fold higher compared to using either drug alone, potentially leading to hospitalization or life-threatening complications. This combination should generally be avoided due to the high bleeding risk. If concurrent use is absolutely unavoidable, the patient must be closely monitored for signs of bleeding (e.g., black stools, unusual bruising, dizziness, fatigue). Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. If an NSAID is necessary, a proton pump inhibitor (PPI) should be co-prescribed to reduce GI bleeding risk.
Combining piroxicam (an NSAID) with enoxaparin (a blood thinner) significantly increases your risk of serious bleeding, including stomach bleeding, which can be life-threatening.
Mechanism
Piroxicam inhibits prostaglandin synthesis, reducing platelet aggregation and damaging the gastrointestinal mucosa. Enoxaparin directly inhibits Factor Xa, preventing clot formation. The additive antiplatelet and anticoagulant effects, along with GI mucosal damage from piroxicam, synergistically increase bleeding risk.
Clinical Management
This combination substantially increases the risk of major bleeding, particularly gastrointestinal bleeding, intracranial hemorrhage, and other site-specific bleeding. The risk of serious GI bleeding can be increased by 3 to 15 times compared to enoxaparin alone. Symptoms may include black, tarry stools; vomiting blood; severe abdominal pain; or unusual bruising. This combination should generally be avoided due to the high bleeding risk. If concurrent use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding, and consideration of gastroprotective agents (e.g., proton pump inhibitors). Alternative pain management strategies or alternative anticoagulants with lower bleeding risk (if appropriate) should be explored.
Combining meloxicam (an NSAID) with enoxaparin (a blood thinner) significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Meloxicam inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa, increasing the risk of bleeding. Enoxaparin directly inhibits Factor Xa, preventing clot formation. The concurrent use of these agents leads to additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also intracranial hemorrhage or other site-specific bleeding. Studies show that NSAID use with anticoagulants can increase GI bleeding risk by 3 to 15 times. Symptoms may include black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from cuts. This combination should generally be avoided due to the high risk of serious bleeding. If co-administration is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding, and for the shortest duration possible. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. If an NSAID is unavoidable, a COX-2 selective agent might be considered, but still carries significant risk.
Combining diclofenac, an anti-inflammatory pain reliever, with enoxaparin, a blood thinner, significantly increases your risk of serious bleeding. This combination should generally be avoided due to the heightened bleeding potential.
Mechanism
Diclofenac inhibits prostaglandin synthesis, leading to reduced platelet aggregation and impaired gastrointestinal mucosal protection. Enoxaparin exerts its anticoagulant effect by inhibiting Factor Xa. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, compounded by the NSAID's direct irritant effect on the GI mucosa.
Clinical Management
The primary risk is a significantly increased chance of major bleeding, including gastrointestinal hemorrhage, intracranial hemorrhage, and other site-specific bleeding. The risk of GI bleeding with NSAID plus anticoagulant is estimated to be 3 to 15 times higher than with anticoagulant alone. Symptoms may include black, tarry stools, blood in vomit, severe abdominal pain, or unusual bruising. This combination should generally be avoided. If concurrent use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding, and only under strict medical supervision. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids. If an NSAID is unavoidable, a COX-2 selective agent might offer a slightly lower GI bleeding risk, but the overall bleeding risk with enoxaparin remains high.
Combining ketorolac with enoxaparin significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Ketorolac, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Enoxaparin is an anticoagulant that inhibits Factor Xa, preventing clot formation. The combination of these two drugs results in additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can be severe or even fatal. This includes gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and bleeding from other sites. The risk of major bleeding can be several-fold higher compared to either drug alone. This combination should be avoided due to the high risk of serious bleeding. If pain management is required, consider alternative analgesics such as acetaminophen or opioids, carefully weighing the risks and benefits. Close monitoring for signs of bleeding (e.g., black stools, easy bruising, unusual bleeding) is crucial if co-administration is unavoidable, but generally, an alternative pain management strategy is preferred.
For complete prescribing information:
View full ENOXAPARIN SODIUM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.